• Connect
  • Bookmark Us
  • AF Twitter
  • AF YouTube
  • AF LinkedIn
  • Subscribe
  • Subscription Link
Arent Fox
  • Firm

    • History

    • Awards & Recognitions

    • Diversity

      • Overview
      • Diversity Scholarship
      • Employees on Diversity
      • LGBT Initiative
      • Women’s Leadership Development Initiative
    • Alumni

    • Pro Bono

      • Overview
      • Current Pro Bono Work
      • Community Involvement
      • Pro Bono Newsletter
      • Pro Bono Awards & Honors
      • FAQ: Pro Bono & Working at Arent Fox
    • Leadership

      • Firm Management
      • Administrative Leadership
  • Deals & Cases

  • People

  • Practices & Industries

    • Practices

      • Advertising, Promotions & Data Security
      • Government Relations
      • Antitrust & Competition Law
      • Health Care
      • Appellate
      • Insurance & Reinsurance
      • Bankruptcy & Financial Restructuring
      • Intellectual Property
      • Commercial Litigation
      • International Trade
      • Communications, Technology & Mobile
      • Labor & Employment
      • Construction
      • Municipal & Project Finance
      • Consumer Product Safety
      • OSHA
      • Corporate & Securities
      • Political Law
      • ERISA
      • Real Estate
      • Environmental
      • Tax
      • FDA Practice (Food & Drug)
      • Wealth Planning & Management
      • Finance
      • White Collar & Investigations
      • Government Contractor Services
    • Industries

      • Automotive
      • Energy Law & Policy
      • Fashion, Luxury Goods & Retail
      • Government Real Estate & Public Buildings
      • Hospitality
      • Life Sciences
      • Long Term Care & Senior Living
      • Media & Entertainment
      • Medical Devices
      • Nonprofit
      • Sports
  • Newsroom

    • Alerts

    • Events

    • Media Mentions

    • Press Releases

    • Social Media

    • Subscribe

  • Careers

    • Lawyers

    • Law Students

    • Professional Staff

  • Contact

    • Washington, DC

    • New York, NY

    • Los Angeles, CA

    Alerts

    • Newsroom Overview
      • Alerts

        Alerts by Criteria

        E.g., 1 / 21 / 2013
        E.g., 1 / 21 / 2013
      • Events
      • Media Mentions
      • Press Releases
      • Social Media
      • Subscribe

    You are here

    Home » Newsroom » Alerts

    Share

    • Printer-friendly version
    • Send by email
    • A Title
    • A Title
    • A Title
    • A
    • A
    • A

    FDA Expands Enforcement Actions against Cosmetic Companies

    September 12, 2012

    On September 7, 2012, the US Food and Drug Administration (FDA) issued a warning letter to cosmetics maker, Greek Island Labs, through its US Agent, Radcliff Consultants LLC, due to product claims on various company websites. The Warning Letter was issued the same day as a similar warning letter to cosmetics maker Lancome USA. In each letter FDA has taken the position that the respective product claims demonstrate the products are “intended to affect the structure and function of the body” rendering them drugs under the Federal Food, Drug, and Cosmetic Act. The Greek Island products cited by FDA include those in the Adonia and Athena lines of products. The specific claims made for the Greek Island products to which FDA objects include, in part, the following:

    • “… helps to strengthen hair growth … and combat … hair loss.”
    • “Eucalyptus also offers antibacterial, anti-inflammatory benefits and can help to stimulate blood circulation on the scalp, encouraging hair growth…”
    • “Human clinical studies have reported that lavender essential oil may be beneficial in … alopecia (hair loss) and as an antibacterial agent.” 
    • “Blemish Free Skin in Just 3 Days!”
    • “Clinically proven to reduce breakouts and blemishes by 84%”
    • “Reduces white heads and black heads by 92%”
    • “…has bactericidal…anti-inflammatory…properties.”
    • “…protect the skin while helping to prevent blemishes.”
    • “…helps in treating a range of skin infections…”
    • “…antiseptic properties help to clear…blemishes…”
    • “…a potent antimicrobial, antibacterial, and antifungal…recommended for many types of skin disorders.”
    • “… effective cell regenerator …”
    • “… cell stimulant and tissue regeneration properties …”
    • “… anti-infectious botanical, as well as an antifungal … also helps in treating a range of skin infections while offering antiseptic … benefits …”
    • “… cell-regenerative for skin, healing for scars (increases production of new cells).”
    • “…reactivate your body’s own dormant and weak skin stem cells, pushing them to regenerate.”
    • “… acts as an … antiseptic and bactericide … It also improves circulation and removes toxins, ensuring optimum circulation.”
    • “… used … to ward off infections …” 
    • “ … used … against plague and fevers.”

    Though FDA has historically objected to the use of claims related to skin conditions like “acne,” and claims that reference “antimicrobial,” “antiseptic,” “anti-inflammatory,” “antifungal” and similar drug-like therapeutic activity, it is clear that FDA is stepping up enforcement activity against makers of cosmetics and cosmeceuticals that use aggressive marketing claims to promote their products. Such enforcement activity may cause some cosmetic product makers to reassess their marketing strategies, especially if they make marketing claims beyond the age-old traditional moisturizing and beauty claims stemming from the definition of a cosmetic established under the FFDCA. Greek Island Labs has 15 days to respond to FDA’s warning letter. We will continue to follow this and other FDA enforcement actions related to cosmetics. For additional information on this issue, please contact Georgia C. Ravitz or Jim Hartten at Arent Fox LLP. A link to FDA’s warning letter follows. Click here to read the warning letter.

    Related People

    • James H. Hartten*
    • Georgia Ravitz

    Related Practices

    FDA Practice (Food & Drug)
    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Contact

    Footer Main

    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Subscribe
    • Alumni
    • Diversity
    • Legal Notice
    • Privacy Policy
    • Social Media Disclaimer
    • Nondiscrimination
    • Site Map
    • Client/Staff Login

    Offices

    • Washington, DC
      1717 K Street, NW
      Washington, DC 20036
      Tel: 202.857.6000
    • New York, NY
      1675 Broadway
      New York, New York 10019
      Tel: 212.484.3900
    • Los Angeles, CA
      555 West Fifth Street, 48th Floor
      Los Angeles, California 90013
      Tel: 213.629.7400
    • © Copyright 2013 Arent Fox LLP. All Rights Reserved.

      Legal Disclaimer
      Contents may contain attorney advertising under the laws of some states. Prior results do not guarantee a similar outcome.